MedTrace Logo

Benefits of Individual Physical Activity Intervention on Health-related Quality of Life in Participants With Chronic Lymphocytic Leukemia

NCT06299540 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 180

Last updated 2026-05-08

No results posted yet for this study

Summary

The purpose of this study is to assess the impact of an individual physical activity intervention (IPAI) on health-related quality of life (HRQoL) in participants with first line or relapsed chronic lymphocytic leukemia (CLL) initiating ibrutinib in a routine clinical practice setting. HRQoL will be measured using functional assessment of cancer therapy - general scale (FACT-G).

Conditions

  • Leukemia, Lymphocytic, Chronic, B-Cell

Interventions

BEHAVIORAL

Individual Physical Activity Intervention (IPAI)

No drug will be administered as a part of this study. The intervention will consist in an IPAI provided to participants for 6 months to practice physical activity in addition to their medical treatment in routine clinical practice settings. IPAI will be an adaptive program and will comprise two periods, the first period consisting in a supervised 4-month program and the second one in an unsupervised 2-month program to achieve greater autonomy.

DRUG

Ibrutinib

No drug will be administered as a part of this study. Participants received ibrutinib as per their routine clinical practice settings.

Sponsors & Collaborators

  • Janssen Cilag S.A.S.

    lead INDUSTRY

Principal Investigators

  • Janssen Cilag S.A.S., France Clinical Trial · Janssen Cilag S.A.S.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-27
Primary Completion
2026-09-30
Completion
2027-10-29

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06299540 on ClinicalTrials.gov